• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 3. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 4. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Latest Research on rel-(2S,3aR,7aS)-Octahydroindole-2-carboxylic Acid (CAS: 87679-58-1) in Chemical Biology and Pharmaceutical Applications

rel-(2S,3aR,7aS)-Octahydroindole-2-carboxylic Acid (CAS: 87679-58-1) is a structurally unique bicyclic amino acid derivative that has garnered significant attention in chemical biology and pharmaceutical research. This compound, characterized by its rigid octahydroindole scaffold, serves as a versatile building block for the synthesis of peptidomimetics and bioactive molecules. Recent studies have explored its potential in drug discovery, particularly in modulating protein-protein interactions and enhancing metabolic stability of peptide-based therapeutics.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the application of this compound in the design of selective protease inhibitors. Researchers utilized its constrained conformation to develop novel inhibitors targeting thrombin, achieving a 15-fold improvement in selectivity compared to linear peptide analogs. The CAS: 87679-58-1 scaffold was found to effectively mimic the β-turn structure in natural substrates, providing critical insights for structure-based drug design.

In neuropharmacology, recent investigations have focused on the compound's potential as a precursor for GABA receptor modulators. A team from MIT reported in ACS Chemical Neuroscience (2024) that derivatives of rel-(2S,3aR,7aS)-Octahydroindole-2-carboxylic Acid showed promising activity as positive allosteric modulators of GABA_A receptors, with improved blood-brain barrier penetration compared to classical benzodiazepines. These findings open new avenues for developing non-sedative anxiolytics.

The synthetic accessibility of this compound has also seen significant advancements. A 2024 Nature Protocols publication detailed an improved asymmetric synthesis route starting from commercially available starting materials, achieving 92% enantiomeric excess and 78% overall yield. This methodological breakthrough addresses previous challenges in large-scale production, making the compound more accessible for medicinal chemistry programs.

Emerging applications in targeted drug delivery systems have been reported in Advanced Drug Delivery Reviews (2023). Researchers functionalized the compound's carboxylic acid group to create pH-responsive drug conjugates, demonstrating enhanced tumor accumulation in mouse models. The rigid bicyclic structure was found to confer stability against enzymatic degradation while maintaining drug release properties.

Ongoing clinical trials (as of Q2 2024) are evaluating derivatives of this compound as potential treatments for fibrotic diseases. Preliminary results suggest that these molecules can effectively inhibit TGF-β signaling pathways with reduced off-target effects compared to current therapies. The unique spatial orientation of functional groups in the 87679-58-1 scaffold appears crucial for this selective inhibition.

Future research directions highlighted in recent review articles include exploring the compound's potential in PROTAC design and as a scaffold for covalent inhibitors. The presence of multiple modifiable positions offers opportunities for creating bifunctional molecules with tailored pharmacological properties. Computational studies predict that further optimization could yield compounds with improved binding kinetics and tissue distribution profiles.

• 80828-13-3((2R,3aR,7aR)-rel-OctahydroIndole-2-carboxylic Acid)
• 80875-98-5((2S,3AS,7aS)-Octahydroindole-2-carboxylic acid)
• 108507-42-2((2R,3aR,7aR)-octahydro-1H-indole-2-carboxylic acid)
• 145438-95-5((2R,3aR,7aS)-Octahydro-1H-indole-2-carboxylic Acid)
• 130092-20-5(D-Proline,4-cyclohexyl-, (4R)-rel- (9CI))
• 145513-93-5((2S,3aS,7aR)-Octahydro-1H-indole-2-carboxylic Acid)
• 103201-78-1((2S,4S)-4-cyclohexylpyrrolidine-2-carboxylic acid)
• 9002-01-1(Streptokinase)
• 145438-94-4((2S,3aR,7aS)-Octahydroindole-2-carboxylic Acid (~90%, contains cis))
• 145513-90-2((2S,3aR,7aR)-octahydro-1H-indole-2-carboxylic acid)